Quercetin 3-(3\'\',4\'\'-diacetylrhamnosyl)-(1->6)-glucoside



Compound IDCDAMM01659
Common nameQuercetin 3-(3\'\',4\'\'-diacetylrhamnosyl)-(1->6)-glucoside
IUPAC name[4-acetyloxy-6-[[6-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-5-hydroxy-2-methyloxan-3-yl] acetate
Molecular formulaC31H34O18

Experimental data

Retention time10.49
Adduct[M+H]+
Actual mz695.183
Theoretical mz695.182
Error0.9
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.3472

Identifiers and class information

Inchi keyOILJXSBGQQNYAQ-AAHLKCTQNA-N
SmilesO=C(OC1C(O)C(OCC2OC(OC=3C(=O)C=4C(O)=CC(O)=CC4OC3C=5C=CC(O)=C(O)C5)C(O)C(O)C2O)OC(C)C1OC(=O)C)C
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)8
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)15
Number of reactive functional groups (#rtvFG)4
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)694.599
Computed dipole moment(dipole)11.707
Total solvent accessible surface area (SASA)989.029
Hydrophobic component of SASA (FOSA)358.848
Hydrophilic component of SASA (FISA)421.441
Pie component of the SASA (PISA)208.74
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1872.48
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)21.15
Free energy of solvation of dipole (dip^2/V)0.0731966
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0565784
Globularity descriptor (glob)0.742849
Predicted polarizability in cubic angstroms (QPpolrz)61.145
Predicted hexadecane/gas partition coefficient (QPlogPC16)22.058
Predicted octanol/gas partition coefficient (QPlogPoct)44.053
Predicted water/gas partition coefficient (QPlogPw)34.162
Predicted octanol/water partition coefficient (QPlogPo/w)-1.051
Predicted aqueous solubility (QPlogS)-4.288
Conformation-independent predicted aqueous solubility (CIQPlogS)-5.579
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.688
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.999
Predicted brain/blood partition coefficient (QPlogBB)-5.432
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.283
Predicted skin permeability, log Kp (QPlogKp)-7.111
PM3 calculated ionization potential (IP(ev))9.037
PM3 calculated electron affinity (EA(eV))0.618
Number of likely metabolic reactions (#metab)8
Prediction of binding to human serum albumin (QPlogKhsa)-1.08
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)299.268
Number of nitrogen and oxygen atoms (#NandO)18
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P22303ACHEAcetylcholinesteraseT30082SwissTargetPrediction
O43570CA12Carbonic anhydrase XIIT16987SwissTargetPrediction and SEA
P16083NQO2Quinone reductase 2T75498SwissTargetPrediction
P43166CA7Carbonic anhydrase VIIT37541SwissTargetPrediction and SEA
P22748CA4Carbonic anhydrase IVT53378SwissTargetPrediction and SEA
P08913ADRA2AAlpha-2a adrenergic receptorT11448SwissTargetPrediction
P15121AKR1B1Aldose reductaseT26623SwissTargetPrediction and SEA
P35354PTGS2Cyclooxygenase-2T66665SwissTargetPrediction
P09917ALOX5Arachidonate 5-lipoxygenaseT00140SEA
Q9HC97GPR35G-protein coupled receptor 35T56143SEA
P18825ADRA2CAdrenergic receptor alpha-2T01777SwissTargetPrediction
P33527ABCC1Multidrug resistance-associated protein 1T11288SEA
P60568IL2Interleukin-2T61698SEA
Q9UNQ0ABCG2ATP-binding cassette sub-family G member 2T56556SEA
P14679TYRTyrosinaseT97035SEA
Q9NPH5NOX4NADPH oxidase 4T29741SwissTargetPrediction and SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SwissTargetPrediction and SEA
P47989XDHXanthine dehydrogenaseT40954SEA
Q16678CYP1B1Cytochrome P450 1B1T92521SEA
Q04760GLO1Glyoxalase IT88285SEA
Q16512PKN1Protein kinase N1T60003SEA
Q9HC98NEK6Serine/threonine-protein kinase NEK6T78992SEA
Q13332PTPRSReceptor-type tyrosine-protein phosphatase ST10147SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
Q15717ELAVL1ELAV-like protein 1T78349SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T30082DI0025Alzheimer disease[ICD-11: 8A20]P22303ACHE
T30082DI0166Glaucoma[ICD-11: 9C61]P22303ACHE
T30082DI0282Myasthenia gravis[ICD-11: 8C6Y]P22303ACHE
T30082DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P22303ACHE
T30082DI0332Pediculosis[ICD-11: 1G00]P22303ACHE
T30082DI0421Unspecific substance harmful effect[ICD-11: NE6Z]P22303ACHE
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T75498DI0214Insomnia[ICD-11: 7A00-7A0Z]P16083NQO2
T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
T11448DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P08913ADRA2A
T11448DI0317Opioid use disorder[ICD-11: 6C43]P08913ADRA2A
T11448DI0396Substance abuse[ICD-11: 6C40]P08913ADRA2A
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T66665DI0087Chronic pain[ICD-11: MG30]P35354PTGS2
T66665DI0145Female pelvic pain[ICD-11: GA34]P35354PTGS2
T66665DI0188Hyper-lipoproteinaemia[ICD-11: 5C80]P35354PTGS2
T66665DI0207Indeterminate colitis[ICD-11: DD72]P35354PTGS2
T66665DI0227Knee osteoarthritis[ICD-11: FA01]P35354PTGS2
T66665DI0320Osteoarthritis[ICD-11: FA00-FA05]P35354PTGS2
T66665DI0324Pain[ICD-11: MG30-MG3Z]P35354PTGS2
T66665DI0366Rheumatoid arthritis[ICD-11: FA20]P35354PTGS2
T66665DI0416Tuberculosis[ICD-11: 1B10-1B12]P35354PTGS2
T00140DI0037Asthma[ICD-11: CA23]P09917ALOX5
T00140DI0147Filariasis[ICD-11: 1F66]P09917ALOX5
T00140DI0403Thrombocytopenia[ICD-11: 3B64]P09917ALOX5
T01777DI0166Glaucoma[ICD-11: 9C61]P18825ADRA2C
T01777DI0190Hypertension[ICD-11: BA00-BA04]P18825ADRA2C
T01777DI0196Hypotension[ICD-11: BA20-BA21]P18825ADRA2C
T01777DI0308Obesity[ICD-11: 5B80-5B81]P18825ADRA2C
T01777DI0310Ocular disease[ICD-11: N.A.]P18825ADRA2C
T01777DI0396Substance abuse[ICD-11: 6C40]P18825ADRA2C
T11288DI0167Gout[ICD-11: FA25]P33527ABCC1
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T56556DI0218Irritable bowel syndrome[ICD-11: DD91]Q9UNQ0ABCG2
T56556DI0366Rheumatoid arthritis[ICD-11: FA20]Q9UNQ0ABCG2
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T29741DI0146Fibrosis[ICD-11: GA14-GC01]Q9NPH5NOX4
T40954DI0206Inborn purine/pyrimidine/nucleotide metabolism error[ICD-11: 5C55]P47989XDH
T40954DI0266Mineral deficiency[ICD-11: 5B5K]P47989XDH
T88285DI0210Influenza[ICD-11: 1E30-1E32]Q04760GLO1
T10147DI0057Bone paget disease[ICD-11: FB85]Q13332PTPRS
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025